News | November 25, 2014

Study of the COBRA PzF Coronary Stent Shows 3% TLR Rate

stents, Cobra, celonova

CeloNova Stent

November 25, 2014 — CeloNova BioSciences, Inc., announced that positive frst-in-man (FIM) clinical trial results found its Cobra PzF coronary stent system with an advanced nano-thin coating of Polyzene-F polymer to be a safe and effective routine interventional treatment for real-world and complex patients with heart disease.
 
Researchers discussed the findings during a live symposium titled “New Therapies Available in Germany but Not in the USA: p-c-i Live in Partnership with TCT.” The symposium was moderated by Dr. Sigmund Silber from Germany, and Dr. Renu Virmani from the United States, at the Transcatheter Cardiovascular Therapeutics (TCT) 2014 meeting.
 
The prospective, single-center study included 100 patients, many of who presented with multi-vessel disease, complex lesions, and co-morbidities such as diabetes, hypertension, dyslipidemia, atrial fibrillation, history of PCI, previous myocardial infarction, and more. Researchers achieved 100% angiographic success. Following treatment, patients were placed on a 30-day anti-coagulant regimen of aspirin (1-2 mg/kg/d) and clopidogrel (1-2 mg/kg/d). At six-month follow-up, results show 0% stent thrombosis, 0% myocardial infarctions, one cardiac death due to terminal cardiac insufficiency (1%), and 3% Target Lesion Revascularization (TLR), leading to 4% Major Adverse Coronary Event (MACE).
 
“The Cobra PzF coronary stent system’s six-month clinical performance is impressive given the wide variety of challenging patients in this study. Even more remarkable, and exciting, are the low TLR and MACE rates as well as the absence of major bleeding complications related to the 30-day limit on dual-antiplatelet therapy,” said Luc Maillard, M.D., Ph.D., lead investigator of the FIM study (The first human experience with novel nano surface modified Cobra PzF Stent). “These data add to recent animal studies showing that Polyzene-F nano-coating technology is associated with rapid healing and re-endothelialization, and may reduce stent thrombosis and restenosis without the use of long-term blood thinning medication.”
 
Coronary stents are thin wire-mesh devices used in minimally invasive interventional procedures to open clogged arteries in the heart. The Cobra PzF coronary stent is made of Cobalt Chromium Super Alloy and is coated with an advanced nano-thin coating of Polyzene-F polymer. The stent platform and the nano-coating technology are designed to impart thrombo-resistance, low inflammation, rapid and natural healing properties. Earlier generation Polyzene-F stents have been studied and results published in scientific journals. CeloNova's Cobra PzF stent builds on this knowledge and improves on the earlier generation Polyzene-F stent technology.
 
“The Cobra PzF coronary stent is designed to satisfy the unmet market need for a device that offers the short dual-antiplatelet therapy regimen associated with bare-metal stents, but with the possibility of lower restenosis rates,” said Kathryn Conner, Senior Vice President, Strategic Marketing, CeloNova Biosciences, Inc. “CeloNova will continue to support the growing body of compelling clinical evidence for this exciting stent platform. We are committed to introducing innovative and disruptive products that significantly improve patient care across the full-care continuum.”
 
In March, CeloNova Biosciences received U.S. Food and Drug Administration approval to begin an investigational device exemption (IDE) trial of the Cobra PzF coronary stent system in the United States.
 
“I am pleased to lead the important IDE trial of this novel device in the U.S.,” said Donald E. Cutlip, M.D., principal investigator and Professor of Medicine, Harvard Medical School. “We recently surpassed a clinical milestone with 100 patients enrolled and look forward to sharing our future findings when data become available.”
 
For more information: celonova.com

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
Overlay Init